iPSC neuron suppliers compared, head to head

The short answer: there is no best supplier, there are four clear winners by criterion. bit.bio is strongest on defined specification and price per cell at volume. BrainXell is strongest on published, usable protocols. Axol is strongest on donor and genotype disclosure. FUJIFILM CDI is strongest on published purity and functional validation depth. iXCells is strongest on breadth of disease mutations at single-vial quantities.

Below is the evidence for each of those statements and, more usefully, the cases where each one is the wrong choice. No supplier can publish this page, because publishing it means naming competitors and conceding categories. That is precisely why it is worth having.

The scorecard

Where each one is genuinely strongest

bit.bio — best defined specification, and the cheapest cells at volume

bit.bio is the only supplier in this group that publishes a subtype-identity release criterion you can quote back at them (>80% VGLUT1/VGLUT2 expression), names the donor including APOE genotype and karyotype, publishes a volume pricing ladder, publishes an academic price, and publishes MEA protocols for two different instrument families. Their disease panel is the broadest published one here, and the CRISPRi-ready, CRISPRa-ready, CRISPRko-ready and GFP backgrounds are priced at the same $999 per 3-vial pack as wild type without media, which effectively makes the engineered background free relative to the base product.

The economics are unusually clear. Wild-type ioGlutamatergic Neurons are $999 for three vials of over one million viable cells, or $4,995 for three vials of over five million — roughly $333 per million at both tiers, which is at or below anything else published here.

When bit.bio is the wrong choice. You cannot buy one vial. The minimum is a 3-vial pack, so a protocol test costs $999 rather than $616. Media is expensive relative to the cells: the same pack with three media kits is $2,046, doubling the price. And the entire wild-type glutamatergic product sits on one donor background — Caucasian male aged 55–60, APOE 3/4 — which is a real confound if your experiment cares about APOE or about donor diversity. Their site also carried a notice that media kits were temporarily deliverable within the UK only while EU and US availability was restored, which is the kind of operational detail that only shows up on the product page.

BrainXell — best published protocols, and the clearest honest timeline

BrainXell publishes the single most useful number in this entire comparison, and it is not a price. Their 24-well MEA co-culture protocol states plainly that neural activity should be present to some degree by 12 days in vitro and will plateau around 21 days. It gives a recommended seeding density of 50,000–100,000 viable neurons per well, a neuron-to-astrocyte ratio of 2:1 to 6:1, a 40 µL seeding droplet placed over the electrodes, a media schedule by day, and the specific Axion plate part number it was validated on.

That is a supplier telling you how long your project is before you have spent anything. Very few do. Their volume pricing is also aggressive: $650 for one million falling to $1,750 for five million, a 46 percent reduction in cost per cell inside one supplier.

When BrainXell is the wrong choice. They do not publish a numeric purity release specification on the public pages we could fetch, so if your quality system needs a threshold in writing before purchase, you will be requesting rather than reading it. Their site also returned an automated-fetch block during our capture, so the prices above are from a same-day capture rather than a continuously verified feed — re-confirm before ordering.

Axol Bioscience — best donor and genotype disclosure

Axol puts the information other suppliers hide in a datasheet directly into the product name. You can see, before clicking anything, that ax0074 is an ALS C9orf72 line from a female donor aged 64, that ax0079 is ALS TDP-43 from a female aged 62, that ax0076 is an unaffected male aged 40–50, and that the cortical range is stratified by APOE genotype across E3/E3, E3/E4 and E4/E4 with both sexes represented.

For any experiment where donor age, sex or APOE status is a confound — which is most neurodegeneration work — that transparency is worth paying for, and it is the reason to choose Axol over a cheaper vial from a less-disclosed background.

When Axol is the wrong choice. The price. Cortical neurons are largely sold as kits including media, supplements and coating, at $2,880 for the unaffected donor and $3,335 for the APOE-genotyped donors, against ≥1.5 million cells. That is a fully-loaded number and not comparable to a bare vial, but it is still the highest entry price in this group. Bare motor neuron vials at $836 for ≥2 million cells are much more competitive. They also do not publish purity specifications or MEA protocols on the storefront.

FUJIFILM CDI — best published purity and the deepest functional validation

FUJIFILM CDI publishes a hard purity number — ≥90% pure glutamatergic — supported by flow cytometry, immunocytochemistry for synaptophysin and Tuj-1, and single-cell gene expression analysis. They then go further than anyone else on functional validation, publishing raster data showing synchronous network bursting and the expected pharmacological responses to convulsants: PTZ-induced GABA receptor block producing arrhythmic activity, and 4-AP potassium channel blockade increasing low-level bursting. They state the neurons remain viable and pure for more than four weeks.

If you are running a seizure liability or neurotoxicity screen and need to justify the model in a regulatory-adjacent document, that published validation package is the strongest here.

When FUJIFILM CDI is the wrong choice. Two catches. First, pricing is stated as “from” and is explicitly valid in the US and Europe only, with separate arrangements for China, South Korea and Japan — do not budget a US list price elsewhere. Second, a product restrictions policy limits the use of some SKUs to provide services to third parties, which is directly relevant if you are a CRO. Also note that a distributor listing states ≥6.0 × 10⁶ viable cells per vial for this product; if that holds on your quote, the per-million economics are far better than the headline suggests, but you must confirm the vial content rather than assuming.

iXCells — best breadth of disease mutations at single-vial quantities

iXCells covers four neuronal subtypes plus astrocytes, NSCs and myoblasts, and prices a wide mutation panel transparently on a public storefront. The motor neuron range alone spans normal ($739), sporadic ALS patient ($1,037), SOD1 A4V homozygous ($1,537) and TDP-43 N352S, Q331K and M337V in heterozygous, homozygous and isogenic-control forms, with the isogenic controls priced back at $739 — the normal-line level.

That last detail is the useful one. Being able to buy a homozygous mutant and its matched isogenic control from the same supplier, on the same storefront, at published prices, is not universal, and it removes a common project failure where the mutant arrives and the control is months out. The full motor neuron price panel across suppliers, normalised per million cells, is on iPSC-derived motor neurons.

When iXCells is the wrong choice. No published purity specification and no published MEA protocol on the storefront, so you are relying on the certificate of analysis and on support conversations for information other suppliers publish. Their primary human skeletal muscle SKUs also return no price at all, routing to contact — fine, but worth knowing before you plan around them.

STEMCELL Technologies and NeuCyte — the specialist cases

STEMCELL Technologies sells forebrain neuron precursors rather than terminally differentiated neurons, manufactured from the named control line SCTi003-A, with the whole STEMdiff ecosystem of maturation, astrocyte and microglia kits built around the same genetic background. If you want neurons, astrocytes and microglia that are genuinely isogenic to each other for a co-culture, that consistency is a real advantage. The offsetting factor is the licence: their published restriction on commercial or monetised use of the cells and derivatives is the tightest we found in this group, with screening permitted only for target discovery, target validation or assay development where the results are not further commercialised. For an academic lab that is irrelevant. For a company it may be disqualifying, and it is better discovered now than after a year of data.

NeuCyte does not sell neurons so much as a defined network. The SynFire system is sold as co-culture kits with a specified composition — in the published MEA configuration, 140,000 glutamatergic neurons, 60,000 GABAergic neurons and 70,000 astrocytes per well on 48-well MEA plates, producing synchronised network bursting at three to four weeks. If your endpoint is excitatory– inhibitory balance rather than a single subtype, buying a validated ratio rather than assembling one yourself is a legitimate shortcut. The trade-off is that the store listing does not publish a price and the system is more prescriptive than buying components.

Choosing by what you are actually doing

Three comparisons that are not real

Bare vial versus kit. Axol’s $2,880 cortical kit and FUJIFILM CDI’s $616 cells-only SKU are not comparable numbers. One includes media, supplements and coating; the other does not. Normalise to a delivered working experiment or do not compare at all.

Different vial sizes. BrainXell at $650 and BrainXell at $1,750 are the same product at 1M and 5M. Comparing a competitor’s 1M vial against that 5M price, or vice versa, measures pack size and not supplier.

Different purity assays. bit.bio’s >80% by transporter gene expression and FUJIFILM CDI’s ≥90% by flow cytometry are not on the same scale. One is a subtype-identity measure, the other a population-purity measure. A higher number is not automatically a better cell.

What we would actually do

Order one vial or one pack from two suppliers whose specifications differ in the way you care about, run them side by side in your own hands on your own instrument, and let that decide. The published information in this comparison is enough to choose which two, and no more than that. Anyone claiming a ranking of these products by performance without side-by-side data in your assay is selling something.

If you want us to source current quotes across several of these against one specification and normalise them to the same counting convention, send us the spec. We hold no volume agreement with any supplier named on this page.